admin, Author at Abcuro

Abcuro to Present Late-Breaking Abstract at American College of Rheumatology Convergence 2021 of ABC008 Inclusion Body Myositis Phase 1 Data Demonstrating Proof of Mechanism for Selective Depletion of Highly Cytotoxic T Cells

November 5, 2021

ABC008 is a first-in-class monoclonal antibody designed to selectively deplete highly cytotoxic T cells ABC008 offers therapeutic potential across a broad range of diseases in addition to inclusion body myositis, such as T cell large granular lymphocytic leukemia (T-LGLL) and mature T cell malignancies Newton, Massachusetts, November 5, 2021– Abcuro, Inc., a clinical-stage biotechnology company developing

November 5, 2021

Abcuro to Present Late-Breaking Abstract at American College of Rheumatology Convergence 2021 of ABC008 Inclusion Body Myositis Phase 1 Data Demonstrating Proof of Mechanism for Selective Depletion of Highly Cytotoxic T CellsPress Releases

Abcuro Appoints Darlene Deptula-Hicks to its Board of Directors

October 19, 2021

Newton, Massachusetts, October 19, 2021– Abcuro, Inc., a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced the appointment of Darlene Deptula-Hicks as a member of the company’s Board of Directors. Ms. Deptula-Hicks is a highly regarded financial executive with decades of experience

October 19, 2021

Abcuro Appoints Darlene Deptula-Hicks to its Board of DirectorsPress Releases

Abcuro to Present Trial in Progress Poster on a Phase 1 Clinical Trial of ABC008 Demonstrating Targeted Depletion of Large Granular Lymphocytes at the 2021 Leukemia, Lymphoma and Myeloma Congress

October 6, 2021

Newton, MA, October 6, 2021– Abcuro, Inc., a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced that a Trial in Progress poster describing a Phase 1 trial of ABC008 will be presented at the Lymphoma, Leukemia and Myeloma Congress Conference being held

October 6, 2021

Abcuro to Present Trial in Progress Poster on a Phase 1 Clinical Trial of ABC008 Demonstrating Targeted Depletion of Large Granular Lymphocytes at the 2021 Leukemia, Lymphoma and Myeloma CongressPress Releases

Abcuro and ImaginAb Share Initial Results of Study Using Novel Technology for Imaging T Cell Infiltration of Skeletal Muscle in Patients with Inclusion Body Myositis

June 30, 2021

Study sponsored by ImaginAb supports hypothesis that CD8+ T cells are present throughout the skeletal muscle system in inclusion body myositis Proprietary ImmunoPET technology developed by ImaginAb provides a more comprehensive view of T cell infiltration than offered by muscle biopsies Newton, MA, June 30, 2021– Abcuro, Inc., a clinical-stage biotechnology company developing therapies for

June 30, 2021

Abcuro and ImaginAb Share Initial Results of Study Using Novel Technology for Imaging T Cell Infiltration of Skeletal Muscle in Patients with Inclusion Body MyositisPress Releases

Abcuro Raises $42 Million in Series A-1 Financing, Appoints John B. Edwards as Executive Chair of the Board of Directors and David de Graaf, Ph.D. as Chief Executive Officer

January 7, 2021

Financing round led by Mass General Brigham Ventures and Sanofi Ventures Proceeds to support advancement of the lead autoimmune program into clinical development, as well as further development of the company’s pipeline Newton, MA, January 7, 2021– Abcuro, Inc., a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer through precise modulation of cytotoxic

January 7, 2021

Abcuro Raises $42 Million in Series A-1 Financing, Appoints John B. Edwards as Executive Chair of the Board of Directors and David de Graaf, Ph.D. as Chief Executive OfficerPress Releases

Abcuro Granted Orphan Drug Designation for ABC008 for Inclusion Body Myositis

June 9, 2020

Inclusion body myositis (IBM)is an autoimmune condition in which cytotoxic T cells chronically attack muscle cells, leading to progressive weakness and severe disability Abcuro’s lead program, ABC008, is an anti-KLRG1 antibody capable of depleting highly differentiated cytotoxic T cells that are pathogenic in IBM Newton, MA, June 9, 2020 – Abcuro, Inc., a clinical-stage biotechnology

June 9, 2020

Abcuro Granted Orphan Drug Designation for ABC008 for Inclusion Body MyositisPress Releases